Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07174726 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
A Phase 2 study of X-Linked Retinitis Pigmentosa (XLRP), sponsored by Beacon Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 6
- Study locations
NCT07174726: Recruiting Phase 2 study of X-Linked Retinitis Pigmentosa (XLRP), sponsored by Beacon Therapeutics.
NCT07174726 is a Phase 2 study of X-Linked Retinitis Pigmentosa (XLRP) that is actively recruiting participants, run by Beacon Therapeutics. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07174726, a Phase 2 study of X-Linked Retinitis Pigmentosa (XLRP), is actively recruiting participants, sponsored by Beacon Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eyes, is safe and works to preserve and/or improve vision and other symptoms of XLRP.
Conditions Studied
Interventions
- BIOLOGICAL Adeno-associated virus vector expressing a human RPGR gene
Study Locations (6)
Florida
- University of Florida Jacksonville Ophthalmology - Jacksonville
- Bascom Palmer Eye Institute - Miami
North Carolina
- Duke Eye Center - Durham
Ohio
- Cincinnati Eye Institute - Cincinnati
Oregon
- OHSU Casey Eye Institute - Portland
Texas
- Retina Foundation of the Southwest - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-09-10 |
| Est. Completion | 2030-12-15 |
| Phase | Phase 2 |
What NCT07174726 shows while recruiting
NCT07174726 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with X-Linked Retinitis Pigmentosa (XLRP) appearing as the primary indexed condition, and to 1 intervention - of which Adeno-associated virus vector expressing a human RPGR gene is the first listed.
NCT07174726 lists 6 locations in 5 states (Florida, North Carolina, Ohio).
Frequently Asked Questions
What is clinical trial NCT07174726 about?
NCT07174726 is a clinical study titled "A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa". The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eyes, is safe and works to preserve and/or improve vision and other symptoms of XLRP.
What is the current status of trial NCT07174726?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-09-10. Estimated completion is 2030-12-15.
What conditions does trial NCT07174726 study?
This clinical trial studies the following conditions: X-Linked Retinitis Pigmentosa (XLRP).
What interventions are being tested in trial NCT07174726?
The interventions under investigation include: Adeno-associated virus vector expressing a human RPGR gene (BIOLOGICAL).
Who is sponsoring clinical trial NCT07174726?
This trial is sponsored by Beacon Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07174726 being conducted?
This trial has 6 study locations across Florida, North Carolina, Ohio, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07174726's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI